Saturday, February 16, 2019
Home Business & Economics

Business & Economics

Studies on Origins of Colon Cancer may Lead to New and More Effective Therapies

Senior Research Scientist Bruce Boman, MD, Ph.D., MSPH, FACP, at the Helen F. Graham Cancer Center & Research Institute of Christiana Care Health System in Wilmington, DE , has received a U.S. $ 916,577 grant from the Lisa Dean Moseley Foundation to further stem cell research into the origins of colon cancer. Funding research and clinical programs undertaken by qualified...

FDA Approves Samsung Bioepis’ First Oncology Biosimilar Trastuzumab-dttb

The U.S. Food and Drug Administration (FDA) has approved trastuzumab-dttb (Ontruzant®; Samsung Bioepis) a biosimilar referencing* trastuzumab (Herceptin®; Genentech/Roche), for adjuvant treatment of HER2-overexpressing (ER/PR-negative o with high risk**) breast cancer, metastatic breast cancer and metastatic gastric cancer or gastroesophageal junction adenocarcinoma in patients who have not received prior treatment for metastatic disease. The agent is Samsung Bioepis’ first oncology...

Financial Toxicity: Privately Insured Cancer Survivors Carry Greater Medical Debt

Younger cancer survivors have are facing significant hardship as a result of their cancer treatment. A recent study also shows that cancer survivors in general carry greater financial burdens  - also referred to as financial toxicity - related to medical debt payments and bills compared with individuals without a cancer history. The result from the study, published online in CANCER,...

Bristol-Myers Squibb and Celgene Merge

Bristol-Myers Squibb Company (headquartered in New York, New York) and Celgene Corporation (headquartered in Summit, New Jersey) have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion. Under the terms of the agreement, Celgene shareholders will receive 1.0 Bristol-Myers Squibb share and...

Rakuten Aspyrian Raises US $284 Million Series C Financing; Develops Photoimmunotherapy Platform

Privately funded clinical stage biotechnology company Rakuten Aspyrian has raised an additional $134 million in a second tranche of its Series C financing, bringing the total amount raised to $284 million. New investors include the SBI Group, Japan and Rakuten. As a result, Rakuten Aspyrian has raised approximately US $ 372 million in equity since the company's founding in...

Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics

Daiichi Sankyo and AnHeart Therapeutics, a clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of innovative medicines, have entered into a worldwide exclusive license agreement to out-license DS-6051, an investigational selective ROS1/NTRK inhibitor, currently in Phase I development for the treatment of patients harboring either a ROS1 or NTRK fusion gene and neuroendocrine tumors. The trials are being...

Phase III AGENT Trial Enrolls First Metastatic Colorectal Cancer Patient

A first patient has been enrolled in the pivotal Phase III AGENT clinical study designed to evaluate arfolitixorin (Modufolin®; Isofol Medical) for the treatment of metastatic colorectal cancer (mCRC). The AGENT trial (NCT03750786) is a randomized, controlled, multi-center study with blinded independent review of the tumor response and is expected to enroll approximately 440 mCRC patients, who are at least...

Gilteritinib Available for Prescription in the United States for Adults with Acute Myeloid Leukemia

Gilteritinib (Xospata®; Astellas Pharma) is now available for prescription in the United States for the treatment of adult patients who have relapsed or refractory (resistant to treatment) Acute Myeloid Leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. An oral monotherapy, gilteritinib is the first and only FLT3-targeting agent approved by the U.S. Food and Drug...

FDA Approves Larotrectinib – the First Tumor-agnostic Cancer Treatment

The U.S. Food and Drug Administration (FDA) has granted accelerated approval for larotrectinib (Vitrakvi® ; Bayer), also know as LOXO-101/ARRY-470 to Loxo Oncology. The novel, anticancer drug is a treatment for adult and pediatric patients whose cancers have a specific genetic biomarker across different types of tumors rather than the location in the body where the tumor originated. This...

Glasdegib Approved in Newly-Diagnosed AML Patients for Whom Intensive Chemotherapy is Not an Option

The U.S. Food and Drug Administration (FDA) has approved glasdegib, also known as PF-04449913 (Daurismo™; Pfizer), a once-daily oral smoothened (SMO) inhibitor for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are 75 years or older or who have comorbidities that preclude use of intensive induction chemotherapy. Acute myeloid leukemia (AML) is the most common type of...

right side

ads

Related articles